REZOLUTE, INC. (RZLT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 11.42M USD | Liabilities, Current |
| Cash and equivalents | 10.62M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 97.19M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.42M | $10.62M | $97.19M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $7.70M | $11.24M | $109.03M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $9.53M | $11.94M | $120.99M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $10.21M | $9.10M | $143.10M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $11.91M | $94.11M | $73.75M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $10.53M | $14.60M | $72.30M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $10.61M | $8.93M | $87.61M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $7.99M | $10.47M | $97.80M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $9.61M | $70.40M | $56.48M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $6.96M | $5.93M | $74.09M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $8.01M | $12.50M | $80.09M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $7.20M | $8.06M | $90.67M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $5.20M | $16.04M | $85.86M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.39M | $33.74M | $69.32M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.31M | $146.75M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $2.43M | $154.32M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $2.46M | $150.41M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $2.88M | $63.42M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $6.45M | $77.40M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.60M | $37.29M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.97M | $41.05M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.59M | $31.99M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.73M | $37.60M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $2.92M | $6.40M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $3.23M | $9.96M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $3.53M | $14.03M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $5.54M | $18.18M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $5.52M | $22.10M | (m) | (m) | (m) | (m) |
| 2019-08-31 | (m) | (m) | $25.20M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $8.38M | $11.57M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $6.62M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.98M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $7.34M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $6.25M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $4.37M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $2.25M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $1.69M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $1.77M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $2.02M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $1.67M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $1.49M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $1.73M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $2.42M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $2.49M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $1.96M | (m) | (m) | (m) | $186.76K | (m) |
| 2015-06-30 | (m) | $1.71M | (m) | (m) | (m) | $67.22K | (m) |
| 2015-03-31 | (m) | $1.80M | (m) | (m) | (m) | $92.42K | (m) |
| 2014-12-31 | (m) | $2.37M | (m) | (m) | (m) | $76.14K | (m) |
| 2014-09-30 | (m) | $892.91K | (m) | (m) | (m) | $301.90K | (m) |
| 2014-06-30 | (m) | $964.04K | (m) | (m) | (m) | $289.60K | (m) |
| 2014-03-31 | (m) | $2.86M | (m) | (m) | (m) | $223.00K | (m) |
| 2013-12-31 | (m) | $6.54M | (m) | (m) | (m) | $223.00K | (m) |
| 2013-09-30 | (m) | $5.68M | (m) | (m) | (m) | $223.00K | (m) |
| 2013-06-30 | (m) | $5.27M | (m) | (m) | (m) | $223.00K | (m) |
| 2013-03-31 | (m) | $5.12M | (m) | (m) | (m) | $223.00K | (m) |
| 2012-12-31 | (m) | $24.47K | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $15.64K | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $10.55K | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $8.85K | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $5.87K | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $5.50K | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $11.66K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |